Supernus Pharmaceuticals filings document regulatory disclosures for a Nasdaq-listed biopharmaceutical company focused on central nervous system diseases. Recent Form 8-K reports cover operating results, conference-call related earnings releases, material definitive agreements, executive compensation arrangements, and other material events tied to the company's CNS product portfolio and corporate obligations.
Proxy materials describe annual meeting voting matters, director elections, advisory executive compensation votes, auditor ratification, and equity incentive plan amendments. The filings also identify the company's common stock structure, exchange listing, shareholder voting mechanics, governance practices, and capital-structure disclosures.
SUPN reports a sale of 5,369 shares of Common Stock. The entry lists Morgan Stanley Smith Barney LLC as the broker and describes the shares as restricted stock vesting under a registered plan with a transaction date of 02/22/2025.
SUPN reported a Form 144 disclosure showing an insider disposition. The filing lists a sale by Todd Horich of 4,438 shares of Common Stock on 03/09/2026 for $239,652.00. The filing also shows restricted stock vesting entries of 394 shares on 02/23/2026 and 4,045 shares on 02/28/2026, each described as employee stock unit awards under a registered plan.
Supernus Pharmaceuticals President and CEO Jack A. Khattar reported routine equity compensation activity involving Performance Share Units that converted into common stock. He exercised derivative awards covering 38,640 Performance Share Units, receiving the same number of shares of common stock.
To cover tax withholding triggered by this vesting, 16,574 shares of common stock were withheld by the company at $54.73 per share, as described in the footnotes. After these transactions, Khattar held 1,228,644 shares of common stock directly and 1,005,600 shares indirectly through the KBT Trust, reflecting a substantial ongoing ownership position.
Supernus Pharmaceuticals SVP Frank Mottola reported a combination of equity compensation events and a small stock sale. He exercised 3,750 Performance Share Units into common stock, with 1,793 shares withheld by the company to cover taxes upon vesting of those units. Shortly after, he executed an open‑market sale of 1,623 common shares at $53.65 per share. Following these transactions, he directly owns 18,440 shares of common stock, reflecting a routine use of vested equity and partial share sale.
SUPERNUS PHARMACEUTICALS, INC. Senior Vice-President & CFO Timothy C. Dec exercised performance share units and settled related taxes in stock. On March 6, 2026, he converted awards into 6,000 shares of common stock, with 2,883 shares withheld at $54.73 per share for tax obligations, leaving 8,232 shares held directly.
Supernus Pharmaceuticals SVP, Commercial Operations William Todd Horich reported a series of stock transactions involving performance-based awards and subsequent sales. On March 6, 2026, he exercised performance share units to acquire 7,500 shares of common stock at $0.00 per share. In connection with this vesting, the company withheld 3,455 shares at about $54.73 per share to cover tax obligations, as disclosed in the footnotes.
He then executed open-market sales of common stock, selling 4,438 shares at $54.00 on March 9 and 4,439 shares at $55.00 on March 10. After these transactions, his directly held common stock position reported in this filing was reduced to zero shares. The filing shows no remaining derivative holdings, indicating all reported performance share units tied to these transactions were fully settled.
Supernus Pharmaceuticals SVP William Todd Horich filed an initial ownership report showing his equity holdings in the company. The filing lists multiple employee stock options on common stock with exercise prices such as $39.4000 and $27.9400, expiring between 2028 and 2036, as well as restricted stock units and performance share units that vest in four equal annual installments beginning on dates including February 23, 2024, February 22, 2025, February 19, 2026 and February 18, 2027. He also holds 4,832 shares of common stock directly.
SUPN filed a Form 144 reporting a proposed sale of 4,438 common shares.
The notice lists restricted stock vesting under a registered plan on 02/19/2026 (544 shares), 02/22/2026 (1,003 shares) and 02/23/2026 (2,891 shares). The broker/agent listed is Morgan Stanley Smith Barney LLC.
Morgan Stanley Smith Barney LLC filed a Form 144 reporting proposed sales of 1,623 shares of Common stock related to restricted stock vesting under a registered plan. The filing lists vesting dates of 01/12/2023, 02/22/2023, and 02/22/2024 with share counts 747, 461, and 415, respectively.